OCT 16, 2013 7:00 AM PDT

Prognostic, predictive, and surrogate biomarkers in men with castration resistant metastatic prostate cancer

C.E. Credits: CE
Speaker
  • Associate Professor of Medicine and Surgery, Duke Cancer Institute, Divisions of Medical Oncology and Urology, Duke University
    Biography
      Andrew J. Armstrong, MD, ScM, is co-program leader of the genitourinary oncology research program, part of the oncology clinical trials shared resource of the Duke Comprehensive Cancer Center. Armstrong is an internationally recognized expert in prostate cancer outcomes studies in men with castration-resistant metastatic disease, including nomograms and risk group models on prognosis. His research is focused on the development of experimental therapeutics in advanced prostate cancer, particularly those targeting the PI3 kinase/mTOR pathways, as well as the development of prognostic and predictive biomarkers of treatment efficacy, particularly with a focus on circulating tumor cell biology and epithelial-mesenchymal transition (epithelial plasticity). Armstrong is the principal investigator on four investigator-initiated clinical trials and approximately 10 industry or cooperative group sponsored clinical trials, as well as several correlative science studies. In addition to co-directing a clinical research program in genitourinary malignancies, Armstrong serves on the Duke IRB and cancer protocol committee, and is an active member of the Duke Comprehensive Cancer Centers editorial advisory and fellowship committees, and serves as the editor of the Duke Prostate Center newsletter [link]. Armstrongs laboratory collaborates with the laboratory of Mariano Garcia-Blanco, MD, PhD, a renowned RNA biologist, to study alternative RNA splicing as it applies to prostate cancer metastasis and EMT. After completing his fellowship in medical oncology at Johns Hopkins in 2006, Armstrong received his masters of science in clinical investigation from the Johns Hopkins Bloomberg School of Public Health in 2008. Armstrong is a recipient of a Prostate Cancer Foundation Young Investigator Award (2008-2011), an American Society of Clinical Oncology Young Investigator Award (2005-2008), an American Association for Cancer Research Clinical and Translational Fellowship (2005-2008), and has received a Department of Defense Prostate Cancer Research Program Physician Research Training Award (2010-2015). He serves on the National Comprehensive Cancer Center's prostate cancer guidelines panel. Armstrong has published extensively on prostate cancer experimental therapies and prognostic models, including peer reviewed articles, reviews, and numerous book chapters and abstracts.

    Abstract

    With the rapid rise in the number of therapeutic options for men with castration-resistant prostate cancer (CRPC) comes increasingly complicated treatment decision-making, emphasizing the need for biomarkers that can identify appropriate patients for specific treatments and accurately assess benefit. While prognostic factors describe natural history, predictive biomarkers are factors related to the disease or the host that are associated with improvements in outcomes, such as survival, due to specific therapies. Surrogate biomarkers provide an early estimate of treatment effect as an intermediate endpoint for outcomes such as survival. Such biomarkers have become of increasing importance in oncology to maximize the benefits of novel systemic agents while minimizing the harms to individual patients and the costs to society. Given the number of newly approved and expensive systemic therapies, including novel hormonal therapies, chemotherapies, immunotherapies, and bone microenvironment-targeting therapies, predictive biomarkers are needed to give physicians a more rational sense of matching the right patient to the right therapy sequence at a given time. Here I discuss prognostic and potential predictive biomarkers in men with CRPC and discuss their potential role in the management of men with metastatic disease. Learning objectives: 1. Define prognostic and predictive biomarkers and apply this knowledge to metastatic prostate cancer patients based on established biomarkers in the castration-resistant setting. 2. Understand the role of surrogate biomarkers in drug development, particularly with respect to metastatic prostate cancer.


    Show Resources
    You May Also Like
    SEP 10, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 10, 2020 9:00 AM PDT
    Date: September 10, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Osmolality testing is relevant throughout the entire bioprocessing workflow. As customers look to refine mAb and gene therapy workf...
    NOV 18, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 18, 2020 8:00 AM PST
    DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
    OCT 29, 2020 6:00 AM PDT
    C.E. CREDITS
    OCT 29, 2020 6:00 AM PDT
    Date: October 29, 2020 Time: 6:00am (PDT), 9:00am (EDT), Chronic inflammation can occur as a result of a combination of genetic predispositions and environmental factors. Epigenetic modifica...
    NOV 16, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 16, 2020 8:00 AM PST
    Date: November 16, 2020 Time: 8:00am (PST), 11:00am (EST) CRISPR screening has become the prime discovery tool in modern biomedical research and drug discovery. At the same time, most screen...
    JUN 23, 2020 10:00 AM PDT
    C.E. CREDITS
    JUN 23, 2020 10:00 AM PDT
    DATE: June 23, 2020 TIME: 10:00am PT Human mesenchymal stromal or stem cells (MSCs)-based immunomodulation treatment has been proposed as a suitable therapeutic approach for many diseases, s...
    C.E. CREDITS
    This drug development program is designed to create a family of broad-spectrum, pan-coronaviral drugs that respectively inhibit multiple key enzymes required for viral replication. By target...
    Loading Comments...
    Show Resources
    Attendees
    • See more